Immunic Therapeutics has closed a private placement that could provide up to $400 million to support the company’s Phase 3 clinical program of vidofludimus calcium in multiple sclerosis (MS) and help fund its transition into a commercial-stage company as it prepares for potential regulatory approval of the…
vidofludimus calcium
Immunic Therapeutics‘ experimental oral therapy vidofludimus calcium can target key mechanisms underlying disease progression in multiple sclerosis (MS), including acute and chronic inflammation, as well as Epstein-Barr virus (EBV) reactivation, according to new trial data. The Phase 2 CALLIPER trial (NCT05054140)Â investigated vidofludimus calcium against a…
Recommended Posts
- Long-term air pollution exposure may increase risk of developing MS: Study
- The silent grief I carry beneath the surface with MS
- Guest Voice: Navigating the uncharted path of living a full life with MS
- New CSF protein markers may help support multiple sclerosis diagnosis
- Caring for others while living with MS requires finding balance